Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis
NCT02908360 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56
Last updated 2021-09-13
Summary
The prevalence of allergic diseases (atopic dermatitis, asthma, rhinitis, conjunctivitis and food allergy) has increased dramatically in industrialized countries over the last 20-30 years.
Allergic diseases are present especially in children and young adults, but all age groups are affected, with variations across countries and age. To propose new therapies, the investigators must first understand the physiopathology.
Since their discovery the regulatory T cells have continued to be the subject of work to understand their role in maintaining immune homeostasis in the human body but also their involvement in autoimmune diseases, inflammatory diseases, transplants of solid organs or fluids and allergic diseases.
It was identified two broad classes of regulatory T cells:
* T cells = natural regulators acquisition of a phenotype and a regulatory function right out of the thymus ( CD25 + / CD127 + low / FoxP3 +).
* T cells induced regulators = acquisition of a phenotype and a regulatory function on the periphery depending on the cytokine micro-environment.
Phenotypic characterization of these is less obvious and even more so than during the last ten years several induced regulatory T cell populations have been described ( eg, Tr1 ).
A new subpopulation of T cells induced in patients with inflammatory bowel disease recently identified have a particular phenotype as bearing the CD4 and CD8 double marking with a regulatory phenotype.
These regulatory T cells are also induced a specific of a commensal intestinal bacterium (Faecalibacterium prausnitzii).
Regarding allergies, it has been widely demonstrated a relationship between changes of the intestinal microbiota and the occurrence of allergic diseases.
The investigators would therefore propose a cross-sectional study, single-center, controlled, single blinded to study the role of T cells called double positive induced regulators DP8 to compare the frequency and the regulatory function of specific DP8 of Faecalibacterium prausnitzii in atopic dermatitis, asthma and allergic rhinitis compared to control samples.
Conditions
- Allergic Asthma
- Allergic Rhinitis
- Atopic Dermatitis
Interventions
- GENETIC
-
double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-07-10
- Primary Completion
- 2017-12-31
- Completion
- 2017-12-31
Countries
- France
Study Locations
More Related Trials
-
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
NCT00329381 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Peanut Immunotherapy
NCT01324401 ·Status: COMPLETED ·Phase: NA
-
Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
NCT04974970 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
NCT03682770 ·Status: COMPLETED ·Phase: PHASE2
-
Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
NCT02874079 ·Status: UNKNOWN ·Phase: NA
-
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
NCT00932282 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dupilumab Therapy for EGIDs
NCT07257835 ·Status: RECRUITING
-
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
NCT06012448 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04322604 ·Status: COMPLETED ·Phase: PHASE3
-
E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy
NCT02879006 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunological Mechanisms Underlying Mucosal IgE Responses
NCT06234761 ·Status: RECRUITING
-
Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects
NCT03070561 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Oral Immunotherapy for Peanut Allergy (PMIT)
NCT00597675 ·Status: COMPLETED ·Phase: PHASE2
-
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
NCT06369467 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
NCT02379052 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT05152563 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
NCT02234934 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Eosinophil Subpopulations in Eosinophilic-associated Diseases
NCT06911775 ·Status: NOT_YET_RECRUITING
-
Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment
NCT01359384 ·Status: UNKNOWN
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
NCT00267501 ·Status: RECRUITING
-
"Clinical and Epidemiological Characteristics of Inflammatory Rhinitis in Patients on Biotherapies"
NCT04132258 ·Status: COMPLETED
-
Gene Therapy for Chronic Granulomatous Disease
NCT00394316 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Multi Immunotherapy to Test Tolerance and Xolair
NCT02626611 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04620811 ·Status: COMPLETED ·Phase: PHASE3
-
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet
NCT05848986 ·Status: UNKNOWN